Skip to main content
Clinical Trials/NCT05226286
NCT05226286
Completed
Not Applicable

Evaluation of Implantable Tibial Neuromodulation Pivotal Study

MedtronicNeuro29 sites in 1 country188 target enrollmentJanuary 31, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overactive Bladder
Sponsor
MedtronicNeuro
Enrollment
188
Locations
29
Primary Endpoint
UUI Responder
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.

Registry
clinicaltrials.gov
Start Date
January 31, 2022
End Date
May 30, 2025
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects 18 years of age or older
  • Qualifying voiding diary
  • Have a diagnosis of UUI for at least 6 months
  • Failed and/or are not a candidate for conservative therapies.
  • Willing and able to accurately complete study diaries, questionnaires, attend visits, operate the system, and comply with the study protocol
  • Willing and able to provide signed and dated informed consent

Exclusion Criteria

  • Have primary stress incontinence
  • History of a prior implantable tibial neuromodulation system
  • Anatomical defects, clinically significant edema or previous surgeries which precludes use of the device
  • Previous pelvic floor surgery in the last 6 months
  • Women who are pregnant or planning to become pregnant during the course of the study
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.
  • Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.

Outcomes

Primary Outcomes

UUI Responder

Time Frame: 6 months

Proportion of TNM subjects experiencing a reduction of 50% or more in daily urinary urge incontinence (UUI) episodes (UUI responder rate) at 6 months after device implant.

Secondary Outcomes

  • UUI Change From Baseline(6 months)
  • UF Change From Baseline(6 months)
  • UPS Change at 6 Months(6 months)
  • OAB-q Change From Baseline(6 months)

Study Sites (29)

Loading locations...

Similar Trials

Related News